Analysis of Clinical Characteristics and Therapeutic Efficacy of Patients with Adult Acute Lymphoblastic Leukemia.
10.7534/j.issn.1009-2137.2020.01.012
- Author:
Ting-Ting XU
1
;
Wei-Min WANG
1
;
Guo-Mei FU
1
;
Jing-Miao WANG
1
;
Zhong-Xing JIANG
2
,
3
Author Information
1. Department of Hematology， The First Affiliated Hospital of Zhengzhou University， Zhengzhou 450052， Henan Province， China.
2. Department of Hematology， The First Affiliated Hospital of Zhengzhou University， Zhengzhou 450052， Henan Province， China,E-mail: jiangzx313@
3. com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):68-75
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical characteristics and therapeutic efficacy of patient with adult acute lymphoblastic leukemia(ALL).
METHODS:Seventy-seven ALL patients diagnosed in the first affiliated hospital of Zhengzhou University from 2018 to 2019 were selected. The immunotyping, fusion gene and gene mutation were detected by flow cytometry, real-time quantitative polymerase chain reaction (RT-PCR) and next generation sequencing (NGS).
RESULTS:Among 77 patients with ALL, 66 were B-ALL, 9 were T-ALL. CD7 and cCD3 were the most valuable for the diagnosis of T-ALL, CD19 and cCD79a were the most valuable for the diagnosis of B-ALL, and CD58, CD123 were highly expressed in B-ALL. Three fusion genes: BCR-ABL (20.8%), MLL-AF4 (5.19%) and E2A-PBX1 (2.60%) were detected by RT-PCR and 10 mutant genes were detected by NGS (the total detection rate was 33.47%). The highest mutation rates were IL-7R (6 cases), NOTCH1 (6 cases), TP53 (5 cases) and FLT-3 (4 cases). Patients with IL-7R, NOTCH1 and TP53 mutations showed poor response to induction chemotherapy.
CONCLUSION:The CD123, IL-7R, NOTCH1 and TP53 may be risk factors for prognosis, however, the increase of case number and prolonging of follow-up time are needed to further confirm.
